| Literature DB >> 34150911 |
Saad Ahmed Sami1, Kay Kay Shain Marma1, Agnila Chakraborty1, Tandra Singha1, Ahmed Rakib1, Md Giash Uddin1, Mohammed Kamrul Hossain1, S M Naim Uddin1.
Abstract
BACKGROUND: COVID-19, a respiratory tract infection caused by SARS-CoV-2, is a burning question worldwide as it gives rise to a pandemic situation. No specific medications are still recommended for COVID-19; however, healthcare support is crucial for ameliorating the disease condition. Pharmacists are the frontline fighters who are responsible for providing healthcare support to the COVID-19 infected patients around the world. This review endeavored to briefly rationalize the contributions of several pharmacy professionals in diverse fields along with their collaborative efforts and dedication regarding their limitations during the COVID-19 situation and view the prospects of pharmaceutical care services in the post-pandemic period. MAIN BODY OF THE ABSTRACT: Online databases were utilized to search for scholarly articles and organizational websites, to sum up the information about the contemporary and expanded role of pharmacists. Key articles were retrieved from Google Scholar, PubMed, and Science Direct databases using terms: "COVID-19," "novel coronavirus," "community," "industrial," "hospital," "clinical," "recognition," "obstacles," "collaboration," "SARS-CoV-2," "healthcare," and "outbreak" in combination with "pharmacist." The articles were included from the inception of the pandemic to January 25, 2021. The current review found pharmacist's global contributions and involvements with other professionals to provide healthcare services amidst COVID-19. This included testing of suspects, providing medical information, psycho-social support, debunking myths, mitigating drug shortage events, telemedicine, e-prescription, infection control, and controlling the drug supply chain. In many countries, pharmacists' activities were much appreciated but in some countries, they were not properly acknowledged for their contributions amidst COVID-19 outbreak. They played additional roles such as participating in the antimicrobial stewardship team, improving value-added services, conducting clinical data analysis to suppress the outspread of the SARS-CoV-2. SHORTEntities:
Keywords: COVID-19; Clinical; Collaboration; Community; Hospital; Industrial; Pharmacist; Recognition
Year: 2021 PMID: 34150911 PMCID: PMC8195448 DOI: 10.1186/s43094-021-00273-9
Source DB: PubMed Journal: Futur J Pharm Sci ISSN: 2314-7245
Fig. 1Overview of global contributions of pharmacists amidst COVID-19
Services provided by community pharmacists in tackling COVID-19 health crisis
| Continents | Country | Community activities |
|---|---|---|
| North America | USA [ | • COVID-19 testing sites in community pharmacies • Gave initial treatment to the patients with allergic symptoms, influenza and Group A Streptococcus. • Performed emergency refill and certain acts without the supervision of a physician, authorized to treat certain conditions, • Performed remote data entry and taking new orders • Mitigated the shortage events of life saving drugs |
| Canada [ | • Daily screening of patients • Offered home delivery services to COVID-19 vulnerable patients • Extending prescriptions and prescribing certain medications alongside doctors | |
| Europe | UK [ | • Carried out online consultation service for patients (Pharmadoctor eTool) • Provided psycho-social support and prescription-free supply of particular controlled medicine to the patients with home-delivery of medicines to the self- isolating patients • Ensured rapid COVID-19 testing service |
| France [ | • Renewal of chronic treatment by community pharmacists • Rights to prepare hydroalcoholic gels in case of shortage • Continuous supply of essential medicine with psycho-social support • Reported the complaints of domestic violence | |
| Italy [ | • Decree for pharmacists to give oxygen to the patients • Introduction of e-prescription and disinfectant products preparation • Continuous supply of essential medicine and home delivery service to vulnerable populations by Federfarma. | |
| Spain [ | • Offered service to the victims of gender violence by requesting a “Mask 19” • Provided clinical screening and interventions • Tele-pharmacy services for chronic disease | |
| Netherlands [ | • Reported the complaints of domestic violence to the pharmacy using code word “Masker 19” • Tele-pharmacy services for chronic disease | |
| Oceania | Australia [ | • Reviewed medication orders and verification • Acted as an “central information center” to provide COVID-19 related information • Extend the supply of medications for chronic diseases • Provided home delivery medication services |
| New Zealand [ | • Provided one-stop pharmacy service that included home-delivery service • Disseminated proper information on community transmission and hand-hygiene | |
| Asia | China [ | • Maintained controlled environment in the community • Ensured regular medical supplies (masks, OTC drugs, disinfectants, thermometer, etc.) and home delivery services through technology • Patient counseling services and served as a custodian of patient safety • Identified probable infections and recorded patients demographic as well as personal information |
| Jordan [ | • Conducted seminars and preparing educational videos related to the COVID-19 infection • Preparation of alcohol-based disinfectants | |
| Taiwan [ | • Proper system for surgical masks distribution and internet based system to check the availability • Provided dispensing services to minimize prescription seeking patients | |
| Macao [ | • Maintained overall infection progress and government approach “The Guaranteed Mask Supply for Macao residents Scheme” | |
| Saudi Arabia [ | • Ensured proper use of medicine to prevent misuse of drugs. • Reported to concerned authority about any suspected case of COVID-19 • Developed informational content such as banner, poster, leaflet to facilitate MOH guideline about COVID-19 among people • Provided home delivery of medicine, telemedicine service and counseling to home quarantined individuals | |
| India [ | • Collected person sample from door to door • Identified patients with symptoms and send them to quarantine • Provided medications and supplies to their communities | |
| Pakistan [ | • Delivered pharmaceutical care through tele-pharmacy to the patient with chronic disease | |
| Qatar [ | • Reviewed medication orders and verification • Participated in COVID-19 screening and testing • Provided home delivery of medications | |
| South America | Colombia [ | • Detection and appropriate referral of possible COVID-19 cases • Provided patient education |
| Brazil [ | • Provided information on COVID-19 • Review of medication history, drug therapy and follow-up • Medication adherence guidance in acute and chronic disease | |
| Africa | Nigeria [ | • Debunked myths of using chloroquine and other unapproved drugs for the cure of COVID-19 • Reviewed medication orders and verification |
| Egypt [ | • Delivered pharmaceutical care through tele-pharmacy to the patient with chronic disease | |
| South Africa [ | • Extend the supply of medications for chronic diseases • Reviewed medication orders and verification | |
| Kenya [ | • Advocated zero-tax implementation on drugs to ensure drug affordability |
Global activities of clinical pharmacists in COVID-19 pandemic
| Continent | Country | Activities |
|---|---|---|
| North America | USA [ | •American College of Clinical Pharmacists (ACCP) made short documentary stories about COVID-19 related practice, information, research, education, and leadership. •Started a new ambulatory care COVID-19 clinic for management of patients after hospital discharge at Ohio, Columbus. •Provided service via telephone calls and collected information by MPN-SAF TSS and DIPSS plus and updated the information to the EMR before patient’s next visit. •A US ID pharmacist from Miami Florida along with other clinical ID pharmacist all over the world started online platform, the |
| Europe | UK [ | •Along with Royal Pharmaceutical Society, United Kingdom Clinical Pharmacists Association started training webinars and clinical resource hub and delivered relevant resources for clinical pharmacists. •Helped in policy making, advocacy and national guidance for pharmacists. •Facilitated in COVID-19 clinical trials, intensive care units (ICU). |
| France [ | •Besides taking care of COVID-19 patients, clinical pharmacists were involved in managing, analyzing and answering questions on an online Q&A hub ( | |
| Asia | China [ | •Provided updated treatment protocols, drug information, new drug therapy report, and helped the physicians as frontline caregivers by managing adverse drug reactions, dosing, drug-drug interactions, etc. •Gave extra attention to particular patient population during the pandemic, e.g., elderly, pregnant, children, patients with previous chronic illness. •Monitored drug-drug interactions for safety concerns such as lopinavir, ritonavir, tocilizumab, interferon, glucocorticoids, and immunomodulatory drugs. •Provided pharmacovigilance research and remote virtual patient counseling. |
| Saudi Arabia [ | •Saudi Society of Clinical Pharmacy (SSCP) published an opinion paper on Pharmacists roles and responsibilities during epidemics and pandemics in Saudi Arabia. •A team of clinical pharmacists was involved in analyzing, publishing, updating and creating treatment protocols for COVID-19 according to the dynamic changes of the pandemic situation. | |
| Qatar [ | •A clinical pharmacist’s team dedicated as the frontline responders for the new established COVID-19 hospitals situated across Qatar and provided clinical interventions and partook in daily rounds. | |
| Thailand [ | •Clinical pharmacist team provided tele-monitoring service on daily basis for every patient by using physician order entry system. •Co-operated with physicians and nurses for handling critical cases of COVID-19. | |
| Lebanon [ | •Clinical pharmacists along with the hospital multidisciplinary teams played crucial and unique roles in this pandemic. At American University of Beirut Medical Center (AUBMC), the ID pharmacist analyzed the information and research papers to establish a local clinical guideline for management of COVID-19. •As frontline caregivers the clinical pharmacists performed therapeutic monitoring of COVID-19 patients and reviewed daily medication regimen | |
| Pakistan [ | •Promptly adapted the national COVID-19 treatment guidelines and provided healthcare to COVID-19 as well as non COVID-19 patients. •Worked beyond their usual duties including, prescribing support, patients medication chart review, ward rounds, and counseling. •Took part in reviewing new updated guidelines and treatment regimen | |
| Africa | South Africa [ | •South African Society of Clinical Pharmacy (SASOCP) published a practice guide for clinical pharmacists presenting the role of clinical pharmacist in COVID-19 |
| Nigeria [ | •Clinical Pharmacy Association of Nigeria (CPAN) started webinars about COVID-19 and its effect on daily work life. •Department of Clinical Pharmacy, The University of Nigeria, Nsukka, Enugu was a part of the National Scientific Advisory Committee for verifying newly established COVID-19 cure. •Pharmacists from the Department of Clinical Pharmacy, in the Africa Resource Centre Nigeria Hub helped to design receptive health supply chain systems for effective distribution of PPE and medicine for different states. | |
| Oceania | Australia [ | •Clinical pharmacists with the National COVID-19 Clinical Evidence Taskforce developed national, evidence based guidelines for the clinical care of COVID-19 patients. •Provided clinical reviews for outpatients via Telehealth and remote counseling. |
The contributions of pharmaceutical companies during COVID-19 pandemic
| Area | Company | Activities |
|---|---|---|
| Treatment development | Alexion | Developed a potential medicine against COVID-19 and it is currently on a phase III clinical trial in hospitalized adult patients. |
| AstraZeneca | R&D teams have promptly started a project with the aim of discovering monoclonal antibiotics that will be effective against novel coronavirus. | |
| Johnson & Johnson | J&J with collaboration are screening existing molecules and also new active compound against COVID-19 virus. | |
| Pfizer | Conducted a preliminary evaluation of some previously developed antiviral compounds and that suppressed the replication of similar coronaviruses to SARS-CoV-2 in cultured cells. | |
| Novartis | Aimed for initiating a phase-III clinical trial of canakinumab among pneumonia patient caused by novel coronavirus. | |
| Amgen | Collaboration with biotechnology company to design and develop antibodies that may become successful to neutralize or inhibit the SARS-CoV-2 virus. | |
| Vaccine development | Seqirus | Working with the University of Queensland to support the CEPI-funded COVID-19 vaccine program based on molecular clamp technology. |
| Sanofi | Work is underway to use a previously developed SARS vaccine with their own recombinant DNA technology. | |
| Pfizer | Pfizer and BioNTech have teamed up to develop a BioNTech mRNA vaccine candidate to prevent COVID-19 infection. | |
| Johnson & Johnson | Expanding partnerships with the Advanced Biomedical Research and Development Authority (BARDA) and establishing new partnerships with Beth Israel Diaconis Medical Center (BIDMC) to accelerate the development of potential novel coronavirus vaccines. | |
| MSD | MSD announced three scientific initiatives, including two agreements with Themis Bioscience and IAVI to develop a potential SARS COVID-19 vaccine, and a partnership with Ridgeback Bio leading the development of new antiviral therapeutics. | |
| Diagnostics | AstraZeneca & GSK | GSK, AstraZeneca, and Cambridge collaborated to set up a new test lab at the University’s Anne McLaren lab. GSK and AstraZeneca are working together to provide process optimization assistance to UK National Test Centers in Milton Keynes, Alderley Park, and Glasgow for COVID-19, and to provide expertise in automation and robotics to support national test systems. |
| Roche | They announced a new antibody test. It is an in vitro test that uses human serum and plasma taken from a blood sample to detect antibodies and determine the body’s immune response to SARS-CoV-2. | |
| Takeda | Working with other pharmaceutical authorities and companies through Europe’s Innovative Medicines Initiative (IMI), we leverage our joint expertise to diagnose COVID-19 and develop inhibitors to prevent future outbreaks. | |
| Helping NHS | Alexion | The Alexion Charitable Foundation has donated funds to three non-profit partner organizations, including the WHO COVID-19 Unity Fund. |
| AstraZeneca | Offered 9 million masks to support healthcare professionals around the world in response to the COVID-19 pandemic. | |
| Johnson & Johnson | Donated £1 million, to London College of Hygiene and Tropical Medicine to guide public opinion on current and potential future actions to curb and treat COVID-19, 30,000 bottles of important toiletries and hand cream worth £250,000 for distribution to healthcare workers, NHS expert. | |
| Novo Nordisk | Working with the NHS, we have opened a new helpline to support diabetics during the outbreak of COVID-19. | |
| Takeda UK | Donated over £100,000 to patient organizations and charities in urgent need. |